Kineta (STU:J75) Short-Term Debt : €0.58 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kineta Short-Term Debt?

Kineta's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.58 Mil.

Kineta's quarterly Short-Term Debt declined from Sep. 2023 (€0.58 Mil) to Dec. 2023 (€0.57 Mil) but then increased from Dec. 2023 (€0.57 Mil) to Mar. 2024 (€0.58 Mil).

Kineta's annual Short-Term Debt declined from Dec. 2021 (€8.85 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.57 Mil).

Kineta Short-Term Debt Historical Data

The historical data trend for Kineta's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Short-Term Debt Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

8.85

0.57

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial							-	0.35	0.58	0.57	0.58

Kineta Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Kineta Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Kineta's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta (STU:J75) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (STU:J75) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

KA:USA

Address

219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Kineta (STU:J75) Headlines

No Headlines